Top Page
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
(2315)
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) vs. iShares MSCI Hong Kong ETF (EWH)
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Business Overview & Revenue Model
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.19B | 980.45M | 716.91M | 533.88M | 354.56M | 253.54M |
| Gross Profit | 946.48M | 761.52M | 506.03M | 391.75M | 247.44M | 166.99M |
| EBITDA | 382.48M | 303.80M | -97.87M | -465.86M | -378.12M | -328.64M |
| Net Income | 132.21M | 33.54M | -382.95M | -602.16M | -545.58M | -542.97M |
Balance Sheet | ||||||
| Total Assets | 2.49B | 2.42B | 2.45B | 2.80B | 2.30B | 2.33B |
| Cash, Cash Equivalents and Short-Term Investments | 486.84M | 381.18M | 408.09M | 611.27M | 566.45M | 957.41M |
| Total Debt | 614.18M | 570.28M | 544.11M | 415.28M | 89.80M | 463.80M |
| Total Liabilities | 1.59B | 1.58B | 1.66B | 1.65B | 1.05B | 868.28M |
| Stockholders Equity | 892.04M | 834.06M | 785.89M | 1.15B | 1.25B | 1.45B |
Cash Flow | ||||||
| Free Cash Flow | 338.66M | 174.12M | -203.26M | -543.94M | -564.45M | -531.73M |
| Operating Cash Flow | 385.07M | 211.25M | -76.65M | -303.27M | -365.78M | -225.31M |
| Investing Cash Flow | -188.05M | -137.12M | -100.28M | -153.74M | -84.13M | -188.18M |
| Financing Cash Flow | -165.85M | -92.03M | -37.82M | 587.20M | 219.44M | 868.44M |
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Technical Analysis
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$14.22B | 97.03 | 16.13% | ― | 48.38% | ― | |
54 Neutral | HK$12.29B | -43.93 | -12.74% | ― | -76.58% | -4.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | HK$9.58B | -16.48 | -42.46% | ― | 1219.19% | 25.15% | |
41 Neutral | HK$16.41B | -57.33 | -8.79% | ― | 964.40% | 65.90% | |
40 Underperform | HK$10.19B | -47.78 | -21.42% | ― | 240.05% | -140.09% |
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Corporate Events
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced that non-executive director Wei Yiliang has resigned from the board, and from his roles on the Audit Committee and the Strategy Development Committee, effective 31 December 2025, citing other work arrangements. The company stressed that Wei has no disagreement with the board, that his departure will not reduce the board below its statutory quorum or disrupt normal operations, and that the board thanked him for his contributions during his tenure, signalling a routine governance change with limited immediate impact on the company’s operations or regulatory standing.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$38.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has announced the current composition of its board of directors, which includes executive, non-executive, independent non-executive and an employee director, led by Chairman, CEO and General Manager Dr. Shen Yuelei. The company also detailed the membership of its four key board committees—Audit, Remuneration and Evaluation, Nomination, and Strategy Development—clarifying which directors serve as chairpersons or members, a move that enhances transparency around corporate governance and delineates oversight responsibilities for stakeholders.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$38.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a Hong Kong-listed pharmaceutical company, announced that its H shares have been included in the list of eligible securities under the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, effective 24 December 2025. The inclusion will allow eligible mainland Chinese investors to directly trade the company’s H shares through the Shanghai and Shenzhen stock exchanges, a move expected to broaden its investor base and potentially boost trading liquidity, with implications for greater market visibility and enhanced access to cross-border capital.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$32.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
Biocytogen Pharmaceuticals has announced the composition of its board of directors, detailing the roles and functions of each member. This update on the board’s structure, including the establishment of four committees, is significant for stakeholders as it reflects the company’s strategic focus on governance and operational oversight.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
Biocytogen Pharmaceuticals has established an Audit Committee under its board of directors to enhance corporate governance. This committee is responsible for reviewing financial disclosures, supervising audit work, and ensuring effective internal controls, thereby replacing the need for a board of supervisors.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
Biocytogen Pharmaceuticals has established a Nomination Committee under its board of directors to regulate the appointment of directors and senior management, aiming to enhance corporate governance. This move is expected to strengthen the company’s operational framework and align with regulatory standards, potentially improving its market position.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
Biocytogen Pharmaceuticals has established a Remuneration and Evaluation Committee under its board of directors to improve its corporate governance structure. This committee is tasked with formulating evaluation standards and reviewing remuneration policies for the company’s directors and senior management, thereby ensuring accountability and strategic alignment with the company’s goals.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
Biocytogen Pharmaceuticals has established a Strategy Committee under its board of directors to enhance strategic development, improve investment decision-making, and strengthen corporate governance. This move aims to bolster the company’s long-term development strategies and major investment decisions, potentially impacting its market positioning and stakeholder interests positively.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
Biocytogen Pharmaceuticals has successfully completed the issuance of A Shares, which will be listed on the Sci-Tech Innovation Board of the Shanghai Stock Exchange starting December 10, 2025. This strategic move is expected to enhance the company’s market presence and provide additional capital for its operations. In addition, Dr. Zhang Haichao has resigned as an executive director due to internal work adjustments, and Ms. Li Yan has been elected as an employee director, marking a significant leadership change within the company.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
Biocytogen Pharmaceuticals announced that its partner, IDEAYA Biosciences, has received FDA clearance for an IND application to initiate a Phase 1 clinical trial of IDE034, a bispecific B7H3/PTK7 antibody-drug conjugate. This milestone underscores Biocytogen’s technical capabilities and highlights the potential of IDE034 in treating various solid tumors, marking a significant advancement in precision-targeted therapeutic strategies.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
Biocytogen Pharmaceuticals has announced the determination of the offer size and price for its A Share Offering, with plans to issue 47,500,000 new A Shares at RMB26.68 per share. This strategic move, following preliminary price consultations, aims to enhance the company’s market presence and leverage its fundamentals, market conditions, and industry valuations, potentially impacting its operations and positioning within the biotechnology sector.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
Biocytogen Pharmaceuticals has submitted a prospectus for the initial public offering of A shares on the Sci-Tech Innovation Board of the Shanghai Stock Exchange. The financial information reveals a significant improvement in the company’s financial performance, with a notable increase in operating income and a shift from a loss to a profit, indicating strong growth and potential positive implications for stakeholders.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
Biocytogen Pharmaceuticals has announced the preliminary price consultation period for its proposed issuance of A Shares on the Sci-Tech Innovation Board of the Shanghai Stock Exchange. The company plans to issue 47,500,000 new A Shares, representing a significant portion of its total share capital. This move is expected to enhance the company’s financial position and market presence, potentially impacting stakeholders by increasing investment opportunities and expanding its shareholder base.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
Biocytogen Pharmaceuticals held its first extraordinary general meeting of 2025, where several key resolutions were approved by shareholders. The meeting, conducted both physically and virtually, saw the approval of the proposed issuance of A Shares and amendments to the company’s Articles of Association, reflecting strategic moves to enhance its market presence and operational framework.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
Biocytogen Pharmaceuticals has announced plans to issue A Shares and list them on the Sci-Tech Board, with the approval process completed by the Shanghai Stock Exchange and CSRC. The proceeds from this issuance will be used to fund various projects, including drug development and evaluation, and to supplement working capital. Additionally, the company plans to amend its Articles and abolish its Supervisory Committee in alignment with the new share issuance.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
Biocytogen Pharmaceuticals has announced its 2025 first extraordinary general meeting, scheduled for November 19, 2025. The meeting will address several key resolutions, including the proposed issuance of A Shares and amendments to company articles and procedural rules. These changes indicate a strategic move towards listing on the Sci-Tech Board, which could enhance the company’s market presence and operational efficiency. Additionally, the meeting will consider the abolishment of the Supervisory Committee, suggesting a shift in governance structure that may impact stakeholder engagement and company oversight.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
Biocytogen Pharmaceuticals has received approval from the China Securities Regulatory Commission (CSRC) for the registration of its proposed initial public issue of A Shares on the Sci-Tech Innovation Board of the Shanghai Stock Exchange. This development is a significant step for the company, although the completion of the share issue is contingent on certain conditions. Stakeholders are advised to exercise caution, and further updates will be provided as necessary.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$23.50 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.